Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
Pemigatinib
Incyte
Unresectable Cholangiocarcinoma
1 trial -
Pergolide
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
1 trial -
Phase 1: Olanzapine
Shanghai Mental Health Center
Schizophrenia
1 trial -
Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy
Hoffmann-La Roche
Relapsed/refractory follicular lymphoma
1 trial -
Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion
Hoffmann-La Roche
HER2-POSITIVE EARLY BREAST CANCER
1 trial -
Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection
Fondazione Telethon ETS
Invasive Breast Cancer
1 trial -
Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.
Hoffmann-La Roche
Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
1 trial -
Pimavanserin
Acadia Pharmaceuticals B.V.
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
2 trials -
Pimodivir 600 mg
Janssen Cilag International NV
Influenza A
1 trial -
Pioglitazone, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, GLIMEPIRIDE, GLICLAZIDE, METFORMIN HYDROCHLORIDE, GLIPIZIDE, METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN, GLIQUIDONE, Placebo for Actos 15 mg tablets, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
Celltrion Healthcare Australia Pty Ltd
Type 2 diabetes mellitus (T2DM)
1 trial -
Placebo
Hoffmann-La Roche
Schizophrenia
1 trial -
Placebo
IRONWOOD PHARMACEUTICALS INC
Irritable Bowel Syndrome With Constipation (IBS-C)
1 trial -
Placebo
Jazz Pharmaceuticals Ireland Limited
Palliative Care
1 trial -
Placebo
BRIGHT MINDS BIOSCIENCES INC.
Substance Abuse
1 trial -
Placebo
Takeda
Male Subjects With Chronic Constipation
1 trial -
Placebo
Pacira Ireland Limited
Postoperative Pain
1 trial -
Placebo
Regeneron UK Limited
Gout
1 trial -
Placebo
Takeda
Non-erosive Gastroesophageal Reflux Disease
1 trial -
Placebo
Hospital Authority, Hong Kong
Congenital Heart Disease in Children
1 trial -
Placebo
Takeda
Chronic Idiopathic Constipation
1 trial -
Placebo
Ono Pharmaceutical Co.,
Chronic Sinusitis
1 trial -
Placebo
Alnylam Netherlands B.V.
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
1 trial -
Placebo
United Therapeutics Europe Ltd
Idiopathic Pulmonary Fibrosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources